Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9736441rdf:typepubmed:Citationlld:pubmed
pubmed-article:9736441lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:9736441lifeskim:mentionsumls-concept:C1166209lld:lifeskim
pubmed-article:9736441lifeskim:mentionsumls-concept:C0021756lld:lifeskim
pubmed-article:9736441lifeskim:mentionsumls-concept:C0024264lld:lifeskim
pubmed-article:9736441lifeskim:mentionsumls-concept:C1538265lld:lifeskim
pubmed-article:9736441lifeskim:mentionsumls-concept:C0596402lld:lifeskim
pubmed-article:9736441lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:9736441lifeskim:mentionsumls-concept:C0599739lld:lifeskim
pubmed-article:9736441lifeskim:mentionsumls-concept:C1511636lld:lifeskim
pubmed-article:9736441lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:9736441lifeskim:mentionsumls-concept:C2349975lld:lifeskim
pubmed-article:9736441pubmed:issue3lld:pubmed
pubmed-article:9736441pubmed:dateCreated1998-11-17lld:pubmed
pubmed-article:9736441pubmed:abstractTextThis report demonstrates that in vitro activation of human cells with the beta-galactoside-specific lectin from mistletoe (ML-I) or interleukin-2 (IL-2) results in different patterns of activation and function of cytotoxic cells. It is now well established that natural killer (NK) and lymphokine-activated killer (LAK) cytotoxicity is mainly mediated by resting (NK) and IL-2-activated (LAK) CD56-positive (+) cells respectively. Culture of peripheral blood lymphocytes (PBL) for 3 days with ML-I led to expansion and activation of T cells which demonstrated NK- and LAK-like cytotoxicity. T lymphocyte subset analysis revealed that in total PBL, ML-I preferentially stimulated and expanded CD8+ T cells which mediated the cytotoxic effect. Incubation of highly purified CD8+ T cells alone with ML-I did not lead to induction of cytotoxicity, which required the presence of both CD4+ and CD14+ (monocytes) cells, suggesting that ML-I does not exert a direct effect on CD8+ T cells. Activation of PBL with both ML-I and IL-2 resulted in simultaneous induction of T and CD56+ cell-mediated NK and LAK cytotoxicity. These data suggest that treatment with ML-I and IL-2 might provide an approach to induce maximum cytotoxicity against tumors and to recruit both T and NK cells for tumor therapy.lld:pubmed
pubmed-article:9736441pubmed:languageenglld:pubmed
pubmed-article:9736441pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9736441pubmed:citationSubsetIMlld:pubmed
pubmed-article:9736441pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9736441pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9736441pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9736441pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9736441pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9736441pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9736441pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9736441pubmed:statusMEDLINElld:pubmed
pubmed-article:9736441pubmed:monthAuglld:pubmed
pubmed-article:9736441pubmed:issn0892-3973lld:pubmed
pubmed-article:9736441pubmed:authorpubmed-author:PapamichailMMlld:pubmed
pubmed-article:9736441pubmed:authorpubmed-author:VoelterWWlld:pubmed
pubmed-article:9736441pubmed:authorpubmed-author:StoevaSSlld:pubmed
pubmed-article:9736441pubmed:authorpubmed-author:BaxevanisC...lld:pubmed
pubmed-article:9736441pubmed:authorpubmed-author:GritzapisA...lld:pubmed
pubmed-article:9736441pubmed:authorpubmed-author:ArsenisPPlld:pubmed
pubmed-article:9736441pubmed:authorpubmed-author:TsitsilonisO...lld:pubmed
pubmed-article:9736441pubmed:authorpubmed-author:SolerM HMHlld:pubmed
pubmed-article:9736441pubmed:authorpubmed-author:VoutsasI FIFlld:pubmed
pubmed-article:9736441pubmed:issnTypePrintlld:pubmed
pubmed-article:9736441pubmed:volume20lld:pubmed
pubmed-article:9736441pubmed:ownerNLMlld:pubmed
pubmed-article:9736441pubmed:authorsCompleteYlld:pubmed
pubmed-article:9736441pubmed:pagination355-72lld:pubmed
pubmed-article:9736441pubmed:dateRevised2009-5-14lld:pubmed
pubmed-article:9736441pubmed:meshHeadingpubmed-meshheading:9736441-...lld:pubmed
pubmed-article:9736441pubmed:meshHeadingpubmed-meshheading:9736441-...lld:pubmed
pubmed-article:9736441pubmed:meshHeadingpubmed-meshheading:9736441-...lld:pubmed
pubmed-article:9736441pubmed:meshHeadingpubmed-meshheading:9736441-...lld:pubmed
pubmed-article:9736441pubmed:meshHeadingpubmed-meshheading:9736441-...lld:pubmed
pubmed-article:9736441pubmed:meshHeadingpubmed-meshheading:9736441-...lld:pubmed
pubmed-article:9736441pubmed:meshHeadingpubmed-meshheading:9736441-...lld:pubmed
pubmed-article:9736441pubmed:meshHeadingpubmed-meshheading:9736441-...lld:pubmed
pubmed-article:9736441pubmed:meshHeadingpubmed-meshheading:9736441-...lld:pubmed
pubmed-article:9736441pubmed:meshHeadingpubmed-meshheading:9736441-...lld:pubmed
pubmed-article:9736441pubmed:meshHeadingpubmed-meshheading:9736441-...lld:pubmed
pubmed-article:9736441pubmed:year1998lld:pubmed
pubmed-article:9736441pubmed:articleTitleMistletoe lectin I-induced effects on human cytotoxic lymphocytes. I. Synergism with IL-2 in the induction of enhanced LAK cytotoxicity.lld:pubmed
pubmed-article:9736441pubmed:affiliationCancer Immunology and Immunotherapy Center, St. Savas Cancer Hospital, Athens, Greece.lld:pubmed
pubmed-article:9736441pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9736441lld:pubmed